Literature DB >> 17689511

Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method.

Andreas Meinitzer1, Markus Puchinger, Brigitte M Winklhofer-Roob, Edmond Rock, Josep Ribalta, Johannes M Roob, Isabella Sundl, Gabriele Halwachs-Baumann, Winfried März.   

Abstract

BACKGROUND: Owing to the growing number of reports in the literature on ADMA as a possibly useful marker of endothelial health, its use in the clinical laboratory is of increasing interest. Age dependency and the small, but statistically significant differences between healthy subjects and disease groups are difficult to interpret. Additionally, levels of ADMA in comparable patient groups of different studies vary widely, even when similar methods have been used.
METHODS: After analytical evaluation of a chromatographic method according to international guidelines, we analysed asymmetrical (ADMA) and symmetrical dimethyl arginine (SDMA), homo-arginine and arginine in EDTA plasma of 292 healthy males aged 20 to 75 years (y) who had passed strict inclusion/exclusion criteria. For statistical analysis, 4 age groups were formed. Group differences were identified with the non-parametric Kruskal-Wallis test.
RESULTS: Calibration curves were linear throughout the selected ranges; the standard deviation for the regression line, recovery, imprecision, and accuracy results were all highly satisfactory. The reference ranges of ADMA for the 4 age groups are presented as age (mean+/-SD of age group, y); number of subjects; median, 2.5th-97.5th percentile: group <35 y: 26.7+/-4.0 y; n=78; 0.58, 0.43-0.69 micromol/L; group 35-49 y: 41.6+/-4.0 y; n=93; 0.59, 0.45-0.73 micromol/L; group 50-65 y: 57.5+/-4.2 y; n=82; 0.61, 0.46-0.78 micromol/L; and group >65 y: 69.6+/-3.3 y; n=39; 0.64, 0.54-0.79 micromol/L.
CONCLUSIONS: Only highly precise methods are able to detect small differences between groups. The application of an evaluated method to a well defined group of healthy subjects should provide a basis for comparison of ADMA concentrations in different patient populations of future studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689511     DOI: 10.1016/j.cca.2007.07.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  18 in total

1.  Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients.

Authors:  S Pilz; A Meinitzer; A Tomaschitz; K Kienreich; H Dobnig; M Schwarz; D Wagner; C Drechsler; C Piswanger-Sölkner; W März; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2012-03-17       Impact factor: 4.507

Review 2.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

3.  Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort.

Authors:  Edzard Schwedhelm; Vanessa Xanthakis; Renke Maas; Lisa M Sullivan; Friedrich Schulze; Ulrich Riederer; Ralf A Benndorf; Rainer H Böger; Ramachandran S Vasan
Journal:  Clin Chem       Date:  2009-06-18       Impact factor: 8.327

4.  Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients.

Authors:  Christiane Drechsler; Andreas Meinitzer; Stefan Pilz; Vera Krane; Andreas Tomaschitz; Eberhard Ritz; Winfried März; Christoph Wanner
Journal:  Eur J Heart Fail       Date:  2011-08       Impact factor: 15.534

5.  Homoarginine and mortality in pre-dialysis chronic kidney disease (CKD) patients.

Authors:  Pietro Ravani; Renke Maas; Fabio Malberti; Paola Pecchini; Maren Mieth; Robert Quinn; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

6.  Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.

Authors:  Viviana Cavalca; Fabrizio Veglia; Isabella Squellerio; Monica De Metrio; Mara Rubino; Benedetta Porro; Marco Moltrasio; Elena Tremoli; Giancarlo Marenzi
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

7.  Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study.

Authors:  Christiane Drechsler; Barbara Kollerits; Andreas Meinitzer; Winfried März; Eberhard Ritz; Paul König; Ulrich Neyer; Stefan Pilz; Christoph Wanner; Florian Kronenberg
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

8.  Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis.

Authors:  Franz Hafner; Andrea Kieninger; Andreas Meinitzer; Thomas Gary; Harald Froehlich; Elke Haas; Gerald Hackl; Philipp Eller; Marianne Brodmann; Gerald Seinost
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

9.  Opposite associations of plasma homoarginine and ornithine with arginine in healthy children and adolescents.

Authors:  Aleksandra Jaźwińska-Kozuba; Jens Martens-Lobenhoffer; Olga Kruszelnicka; Jarosław Rycaj; Bernadeta Chyrchel; Andrzej Surdacki; Stefanie M Bode-Böger
Journal:  Int J Mol Sci       Date:  2013-11-04       Impact factor: 5.923

10.  Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes.

Authors:  Norbert J Tripolt; Sophie H Narath; Michaela Eder; Thomas R Pieber; Thomas C Wascher; Harald Sourij
Journal:  Cardiovasc Diabetol       Date:  2014-05-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.